5 Stocks Crushing the Market With Surging Returns

4. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)

Iovance Biotherapeutics climbed by 15.57 percent on Thursday to end at $4.38 apiece after securing the conditional approval of Australia’s Therapeutic Goods Administration (TGA) for the treatment of melanoma through its therapy, Amtagvi.

The approval marked Iovance Biotherapeutics Inc.’s (NASDAQ:IOVA) third marketing authorization for Amtagvi, after earlier securing the approval of the US and Canada.

The company posted an optimistic outlook about Amtagvi’s business prospects in Australia, with the country having the highest rate of melanoma globally, with an estimated 17,000 new cases diagnosed each year and more than 1,500 deaths annually.

“This approval … marks a significant step forward for Iovance in the country with the highest rate of melanoma globally,” Iovance Biotherapeutics Inc. (NASDAQ:IOVA) President and CEO Frederick Vogt.

“We are in the process of authorizing our first Australian treatment center as we advance our expansion strategy for Amtagvi in additional markets with a high prevalence of advanced melanoma.”

TGA granted approval based on safety and efficacy results from the global, multicenter C-144-01 trial investigating Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 therapy and targeted therapy, if applicable.